N-[(3-methylimidazol-4-yl)methyl]-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-5-propylpyrazole-4-carboxamide | 1019254-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[(3-methylimidazol-4-yl)methyl]-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-5-propylpyrazole-4-carboxamide
• 英文别名: N-[(1-methyl-1H-imidazol-5-yl)methyl]-1-[5-methyl-4-(2-thienyl)pyrimidin-2-yl]-5-propyl-1H-pyrazole-4-carboxamide；Insulin levels modulator；N-[(3-methylimidazol-4-yl)methyl]-1-(5-methyl-4-thiophen-2-ylpyrimidin-2-yl)-5-propylpyrazole-4-carboxamide
• CAS: 1019254-94-4
• 化学式: C₂₁H₂₃N₇OS
• 分子量: 421.526
• InChiKey: CCIGHGGCWSBIPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• N-aryl pyrazole compounds, compositions, and methods for their use
  申请人：Ogawa Yasuyuki

  公开号：US20080153778A1

  公开（公告）日：2008-06-26

  Compounds having formula I: where A 1 , A 2 , L, V, W, R 1 , R 2 , R 3 , R 4 and R 5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.

  本文提供化学式为I的化合物，其中A1、A2、L、V、W、R1、R2、R3、R4和R5如本文所述，以及其组合物，并用于治疗或预防2型糖尿病和2型糖尿病相关疾病。
• N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES
  申请人：Amgen Inc.

  公开号：EP2079728B1

  公开（公告）日：2013-09-25
• GPR142 AGONIST COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：EP3105207B1

  公开（公告）日：2018-08-22
• GPR142 Agonist Compounds
  申请人：Eli Lilly and Company

  公开号：US20170165234A1

  公开（公告）日：2017-06-15

  The present invention provides compounds of the Formula (Ia) wherein R is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CN, CH 2 CHF 2 , CH 2 CF 3 , (A), (B), (C), (D), (E), (F), CH 2 CH 2 OCH 3 , and CH 2 C(O)OCH(CH 3 ) 2 ; R 1 is selected from the group consisting of CF 3 , OCF 3 , and Cl; R 2 is selected from the group consisting of H and F; or a pharmaceutically acceptable salt thereof.
• US8022061B2
  申请人：——

  公开号：US8022061B2

  公开（公告）日：2011-09-20